Jianing Wang is an Assistant Investigator at MGH Biostatistics. Her methodological research centers around advancing indirect methods for hidden population size estimation and spatial and hierarchical modeling approaches for disease characterization and population dynamic prediction. In addition to her extensive collaborative experience in HIV, Hep C, and substance use disorder outcome research, she has been developing an innovative statistical framework for knowledge transfer between large-scale health surveillance systems, as well as the approaches pertinent to neurological disease investigations. Currently, she is involved in projects including HEALEY ALS platform trials, the NIH HEAL Initiative, and the development of a novel community-based high-performance surveillance network for substance misuse.
Dr. Wang completed her PhD in Biostatistics from the Boston University School of Public Health and her MS in Applied Statistics from Boston University.
Zoe Guan is an Assistant Investigator at MGH Biostatistics. Her methodological research focuses on risk prediction and the analysis of next-generation sequencing data. Her collaborative research areas include cancer and COVID. She is involved in the DF/HCC Lung Cancer SPORE, as well as the NIH RECOVER project on long COVID. Before joining MGH Biostatistics, she was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center.
Dr. Guan received a PhD in Biostatistics from Harvard University and a BSc in Mathematics and Computer Science from McGill University.
Harrison Reeder (he/him) is an Instructor in Investigation at MGH Biostatistics and an Instructor in Medicine at Harvard Medical School. His biostatistical research focuses on analysis methods and risk prediction tools for complex survival data, especially in the setting of “semi-competing risks.” He collaborates with multiple groups at MGH, including the Center for Addiction Medicine, and the RECOVER Project study of post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID. His collaborative research also includes work on a variety of topics including perinatal health and cognitive health in older adults.
Dr. Reeder received his BA in Mathematics/Statistics from Carleton College and PhD in Biostatistics from Harvard University.
Susanne S. Hoeppner is an Assistant Professor of Psychiatry at Harvard Medical School (HMS) and is a member of Massachusetts General Hospital (MGH) Biostatistics. She provides statistical guidance and expertise for various groups at MGH including the Center for OCD and Related Disorders (CORD), the Medical Practice Evaluation Center (MPEC), and the Recovery Research Institute (RRI). Her collaborative research effort has included applications in psychology, psychiatry, smoking cessation, and HIV/AIDS. She has served as the principal statistician on pivotal trials approved by the FDA and has designed and analyzed Phase I-III studies in addiction, psychiatry, and psychology. She also has ample experience setting up, updating, and overseeing the use of electronic data capture forms as implemented via REDCap, having designed and managed such databases for several single- and multi-site clinical trials at MGH. Dr. Hoeppner’s clinical interests are in dynamic health behavior modeling and positive psychology.
Dr. Hoeppner earned a PhD in Oceanography and Coastal Sciences and her Master of Applied Statistics from Louisiana State University. She also holds a MS in Biological Science from Southeastern Louisiana University.
Joseph J. Locascio, Ph.D. has had a research appointment as a Senior Biostatistician for the Alzheimer’s Disease Research Center and Memory/Movement Disorders Units, Department of Neurology at Massachusetts General Hospital (MGH), Boston, since 1992. He is an Assistant Professor of Neurology at Harvard Medical School as well as a Collaborating Statistician in the Neurology Dept. at Brigham and Women’s Hospital. He is a Consulting Statistician for the Harvard Catalyst Bio-Statistical Consulting Group of Harvard Medical School, and a member of the Statistical Advisory Boards for the journals PLOS One (Public Library of Science) and Lancet-Neurology.
Previously, Dr. Locascio had a dual appointment as research statistician in the Department of Brain and Cognitive Sciences at the Massachusetts Institute of Technology (MIT) from 1992 to 2009 where he also taught formal data analysis courses for four years. He has also taught statistics at Northwestern University (1982) and worked as a statistician in psychiatric research at the University of Chicago (1983-1985) and Bellevue Hospital/New York University Medical Center (1989-1991), and was Research Coordinator for the Mental Health Division of the Chicago Dept. of Health (1976-1979). He has over 100 publications in medical and scientific journals, magazines, and books.
Mark Vangel is an Assistant Professor of Radiology at Harvard Medical School and an Assistant Investigator at MGH Biostatistics and the Martinos Center for Biomedical Imaging at MGH. He is also affiliated with the Ferenc Jolesz National Center for Image Guided Therapy at Brigham and Women’s Hospital and the Clinical Research Center at MIT.
His research interests include heteroscadasticity in meta-analysis and mixed-model regression, measurement uncertainty, statistical applications in functional MRI and diagnostic imaging, and Bayesian applications.
Dr. Vangel earned a PhD in Statistics from Harvard University, and SM and SB degrees in Mathematics from MIT.
Beow Yeap has collaborated closely with investigators in radiation oncology, radiation physics, medical oncology, molecular pathology, and thoracic surgery at the MGH Cancer Center and Dana-Farber/Harvard Cancer Center since joining MGH Biostatistics in 1999. She has developed extensive experience and expertise in design and analysis of clinical trials and correlative studies for adult and pediatric tumors, with primary focus on proton radiation therapy and molecularly targeted therapies.
Her contributions to translational research encompass preclinical models as well as human studies, including the identification and validation of biomarkers for prognosis and prediction of therapeutic benefit. She has played a leadership role in multi-disciplinary, multi-institutional research efforts as Director of the Biostatistics Core for the Program Project in proton therapy research and DF/HCC SPORE in Lung Cancer.
In between her degree studies for an A.M. in Statistics from the Harvard Graduate School of Arts & Sciences and an Sc.D. in Biostatistics from the Harvard T.H. Chan School of Public Health, she gained valuable experience in cancer clinical trials at the Dana-Farber Cancer Institute.
